TIMI

Mar 16, 2020

Provention Bio Provides Update on the Status of Its Phase 3 PROTECT Study for the Treatment of Newly Diagnosed Type 1 Diabetes

Jan 22, 2020

Tencent's TiMi Studios Named Best Developer At Pocket Gamer Mobile Games Awards

Sep 20, 2019

CathWorks FFRangio(TM) System Featured In TCT 2019 Satellite Program

Jun 09, 2019

Dapagliflozin Reduces Progression of Kidney Disease and Renal Death in People with Type 2 Diabetes

Nov 10, 2018

Forxiga significantly reduced hospitalisation for heart failure or CV death in a broad patient population with type-2 diabetes in the landmark DECLARE-TIMI 58 trial

Aug 27, 2018

Eisai Announces Long-Term Cardiovascular Outcomes Data for Anti-Obesity Agent BELVIQ® Presented at the European Society of Cardiology and Published in the New England Journal of Medicine

Jul 17, 2018

Eisai Inc. Announces Positive Topline Results from CAMELLIA-TIMI 61, a Large-Scale Cardiovascular Outcome Trial for the Anti-Obesity Agent BELVIQ®

Feb 01, 2018

Cardiovascular Systems, Inc. Announces Commercial Launch in Japan

Jun 21, 2017

Eisai Announces Lorcaserin HCl CAMELLIA-TIMI 61 Study will Continue as Planned Based on Interim Safety Analysis by Independent Data Monitoring Committee (DMC)

Jun 01, 2017

First ultra-sensitive cardiac troponin (cTnI) test using Single Molecule Counting technology receives CE Mark